Allogene Therapeutics said Zachary Roberts will succeed David Chang as president and CEO after Chang’s eight-year tenure at the off-the-shelf CAR-T company. The move is set to take effect July 1 for Roberts as he also joins the board, with Chang continuing on the board. The leadership change comes as the company continues to operate in a competitive CAR-T landscape where next-wave platform differentiation—manufacturing, logistics, and clinical depth—remains central to investor and partner confidence. Roberts’ appointment aligns with internal product and development ownership given his prior roles as executive vice president of R&D and chief medical officer at Allogene.